Fumio Nakagawa

Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models

Nozomu Tanaka, Kazuki Sakamoto, Hiroyuki Okabe et al. · Oncology Reports · 2014 · 140 citations · Full text

Antitumor Activity, Medicine, Tumor Growth +14

Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts

Hiroshi Tsukihara, Fumio Nakagawa, Kazuki Sakamoto et al. · Oncology Reports · 2015 · 109 citations · Full text

Combination Chemotherapy, Medicine, Pharmacology +12

A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells

Tomohiro Emura, Yuko Murakami, Fumio Nakagawa et al. · International Journal of Molecular Medicine · 2004 · 105 citations

Pathology, Cancer Biology, Liver Metastasis +17

An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA

Tomohiro Emura, Fumio Nakagawa, Akio Fujioka et al. · International Journal of Molecular Medicine · 2004 · 85 citations

Pharmaceutical Science, Chemical Biology, Culture Medium +21

Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo

Masakazu Fukushima, A Fujioka, Junji Uchida et al. · European Journal of Cancer · 2001 · 79 citations

Tumor Biology, Ribonucleotide Reductase, Oncogenic Agent +9